Fate Therapeutics, Inc. (FATE)
| Market Cap | 8.41B |
| Revenue (ttm) | 31.43M |
| Net Income (ttm) | -173.39M |
| Shares Out | 82.39M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $89.72 |
| Previous Close | $86.27 |
| Change ($) | 3.45 |
| Change (%) | 4.00% |
| Day's Open | 88.67 |
| Day's Range | 84.02 - 93.29 |
| Day's Volume | 1,195,351 |
| 52-Week Range | 16.75 - 121.16 |
FATE reports a wider Q4 loss on increased R&D expenses.
Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61...
Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...
The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while it's up 13% over the last ten trading days, and we believe the rally may continue in the n...
Time will always be on the investor's side.
These two companies are at the forefront of innovation during our golden age of biotech.
After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a biopharmaceuticals company focused on oncolo...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...
If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.
SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...
Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
The biotech's natural killer cell therapies have real potential.
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.
The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.
The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.
Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherap...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherap...
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma
SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunothera...
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunothe...
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunother...
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call Transcript
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...
Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunother...
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunother...
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Probably, but it depends on whether the company can deliver on its cost-cutting potential.
Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients
Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo...
The cell therapy developer announced the next step for an important pipeline asset.
The company has some additional capital to support the development of its pipeline.
SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo...
About FATE
Fate Therapeutics, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of adv... [Read more...]
| Industry Biotechnology | IPO Date Oct 1, 2013 |
| CEO William Rastetter | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol FATE |
Financial Performance
In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.
Analyst Forecasts
According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 103.00, which is an increase of 14.80% from the latest price.